Vienna, Austria, Friday 16 April: Results of an international clinical study conducted in Europe and the US presented today at the International Liver CongressTM 2010, the Annual Meeting of the European Association for the Study of Liver in Vienna, Austria, have identified a genomic portrait able to predict recurrence in hepatocellular carcinoma (HCC), the fifth most common cancer in men .
HCC is a primary cancer of the liver. Worldwide, it accounts for approximately 5.4% of all cancers1 and it is the third cause of cancer-related death with more than 660,000 deaths per year1. Only around 20-30% of patients are treated with curative treatments, including resection and local ablation, but recurrence complicated the outcome in more than two thirds of these cases .
Results of this study identified two gene signatures- one coming from the tumor and the other from the cirrhotic liver - able to identify patients with poor disease outcome. The study concluded that these genetic tools can ultimately be used to select patients for preventive therapies. In addition, specific genes included in these signatures should be evaluated as potential targets for adjuvant treatment, following surgical intervention in HCC patients.
Dr Josep Llovet, Professor from the Hospital Clinic of Barcelona-IDIBAPS and Mount Sinai School of Medicine in New York, who led the study and highlighted this topic at EASL's official press conference said, "The results of our study demonstrate the potential that molecular classification offers to future clinical management of diseases such as HCC. By successfully identifying certain genomic signatures that clearly predict both overall and early recurrence of HCC post-surgery, we now have a clearer focus for future research into therapeutic options that may in time improve patients' chances of survival".
The study was presented at EASL by Augusto Villanueva, MD member of the International HCC Genomic Consortium. The genomic profiles of 287 HCC patients using whole-genome gene expression platforms were analysed. The study focussed on patients with early HCC (n=257, principally male 189/257, with a mean age of 64) with tumoral tissue (n=257) and adjacent non-tumoural cirrhotic tissue (n=209). Patients were on average followed up after 46 months - there were 167 recurrences (64%) and 89 deaths (34%). In total, 20 gene signatures were evaluated with reported ability to predict survival and or recurrence of HCC. Genomic signatures from the tumour (Proliferation-G3) and adjacent tissue (with poor prognosis) of patients with HCC were identified as important in predicting both overall and early recurrence in HCC. The multinodularity gene signature was also identified as a predictor for HCC recurrence while tumor size was identified as predictor for early recurrence.
EASL is the leading European scientific society involved in promoting research and education in hepatology. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European Liver policy.
EASL's work continues throughout the year with numerous events and initiatives, including:
- The International Liver CongressTM which lasts several days and attracts upwards of 7,500 participants
- EASL meetings including Monothematic and Special conferences, Post Graduate courses and other EASL endorsed meetings that take place throughout the year
- EASL Clinical and Basic Schools of Hepatology, a series of events covering different aspects in the field of hepatology
- Journal of Hepatology published monthly with a readership of over 40,000
- Presenting new initiatives for European liver policy change
About The International Liver CongressTM 2010
The International Liver Congress™ 2010, the 45th annual meeting of the European Association for the study of the Liver, is being held at the Reed Messe Wien congress center, Vienna, Austria from April 14th-18th, 2010. The congress annually attracts over 7,500 clinicians and scientists from around the world and provides an opportunity to hear the latest research, perspectives and treatments of liver disease from principal experts in the field.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005; 55:74-108.
Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362(9399):1907-1917.Hoshida Y, Villanueva A, Kobayashi M et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359(19):1995-2004.